GH (basal and during Oral Glucose Tolerance Test (OGTT)) and IGF-1 levels, in acromegalic patients previously treated with octreotide long acting release (LAR) 20 mg. Weeks 16, 18 & 20 [clinicaltrials_resource:3d1f6bd26b1a02b4f5206a3a550a4562]
120 mg administered every 28 days via deep subcutaneous injection. A total of 4 injections will be administered during the study.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
GH (basal and during Oral Glucose Tolerance Test (OGTT)) and IGF-1 levels, in acromegalic patients previously treated with octreotide long acting release (LAR) 20 mg. Weeks 16, 18 & 20 [clinicaltrials_resource:3d1f6bd26b1a02b4f5206a3a550a4562]
120 mg administered every 28 days via deep subcutaneous injection. A total of 4 injections will be administered during the study.
Bio2RDF identifier
3d1f6bd26b1a02b4f5206a3a550a4562
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:3d1f6bd26b1a02b4f5206a3a550a4562
measure [clinicaltrials_vocabulary:measure]
GH (basal and during Oral Gluc ...... ng acting release (LAR) 20 mg.
time frame [clinicaltrials_vocabulary:time-frame]
Weeks 16, 18 & 20
description
120 mg administered every 28 d ...... administered during the study.
identifier
clinicaltrials_resource:3d1f6bd26b1a02b4f5206a3a550a4562
title
GH (basal and during Oral Gluc ...... (LAR) 20 mg. Weeks 16, 18 & 20
@en
type
label
GH (basal and during Oral Gluc ...... f6bd26b1a02b4f5206a3a550a4562]
@en